International Journal of Radiation Oncology * Biology * Physics This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Scalp Irradiation with 3D-Milled Bolus: Dosimetric, Toxicity, and Oncologic Outcomes
Bolus is required when treating scalp lesions with photon radiation therapy. Traditional bolus materials face several issues, including air gaps and setup difficulty due to irregular, convex scalp geometry. 3D-milled bolus is custom formed to match individual patient anatomy, allowing improved dose coverage and homogeneity. Here, we report outcomes for patients with scalp malignancies treated with Volumetric Modulated Arc Therapy (VMAT) utilizing 3D-milled bolus. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: G. Tocaj, K. Dibs, S.R. Jhawar, S. Baliga, J.C. Grecula, D.L. Mitchell, J.D. Palmer, K.E. Haglund, T.Y. Andraos, W. Zoller, A. Ewing, M. Bonomi, P. Bhateja, G. Tinoco, D. Liebner, J.W. Rocco, M. Old, A. Chakravarti, D.J. Konieczkowski, D.M. Blakaj, E. Gog Tags: 239 Source Type: research
Observational Cohort Study of Immune Checkpoint Inhibitor Therapy for Anaplastic and Poorly Differentiated Thyroid Carcinoma
This study aims to evaluate the efficacy and tolerability of ICIs for the treatment of ATC and PDTC in a real-world cohort which may not have met the inclusion criteria of previous trials. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: O. Elghawy, L. Sun Tags: 240 Source Type: research
Expression of Circulating Prostate-specific Membrane Antigen Extracellular Vesicles in Blood of Patients with Recurrent and Metastatic Salivary Gland Cancer
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein known to be overexpressed in prostate cancer and certain types of salivary gland cancer (SGC). Extracellular vesicles (EVs) are membrane-bound vesicles released from cells that are emerging as a promising blood biomarker for disease monitoring. The purpose of this exploratory analysis is to determine if circulating PSMA EVs can be detected in patients with recurrent or metastatic (R/M) SGC and to explore whether the direction of PSMA EV change correlates with tumor volume change. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: K. Price, P.W. McGarrah, E. Horjeti, N.R. Foster, E.J. Asmus, B. Baral, H. Fuentes Bayne, C. Fazer-Posorske, B.J. Burkett, S.C. Lester, D.M. Routman, F. Lucien-Matteoni Tags: 241 Source Type: research
Survival Outcomes following Pulmonary Metastasis-Directed Local Therapy (PM-LT) Relative to No Metastasis-Directed Intervention in Adenoid Cystic Carcinoma (ACC)
ACC has a high rate of recurrence and distant metastasis (DM), despite aggressive curative-intent primary therapy. The lung is the most common site of DM, most often with indolent disease growth. Given the lack of FDA-approved systemic therapy for metastatic ACC, PM-LT is frequently used. The survival impact of PM-LT is not known and there is no consensus on whether routine PM-LT is appropriate. The purpose of this study was to assess the survival outcomes of ACC patients (pts) who underwent PM-LT and compare to those who did not. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: C.O. Hoff, L. Feng, F. Bonini, L.G. Sousa, K. Wang, J.M. Siqueira, A. Purushothaman, Q.N. Nguyen, A.K. El-Naggar, R. Mehran, R. Ferrarotto Tags: 242 Source Type: research
Efficacy and Tolerability of Vascular Endothelial Growth Factor Receptor Inhibitors (VEGFRi) for Recurrent/Metastatic Adenoid Cystic Carcinoma (R/M ACC): a Systematic Review and Meta-Analysis
ACC has a high rate of recurrence and distant metastasis. There is no FDA-approved systemic therapy for R/M ACC. Given high VEGFA expression in ACC and association with poorer prognosis, various clinical trials have assessed VEGFRi in R/M ACC but are mostly single-arm studies with small sample sizes. The relatively low level of evidence has led to debate over the adoption of VEGFRi in ACC management. Given remaining uncertainty, we performed a systematic review and meta-analysis evaluating efficacy, safety, and tolerability of VEGFRi in R/M ACC. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: C.O. Hoff, J. Manzi, F. Lazar Neto, R. Ferrarotto Tags: 243 Source Type: research
Prognostic Value of Time To Progression vs. Tumor Volume Doubling Time in Patients with Adenoid Cystic Carcinoma Metastatic To The Lung
The objective of this study was to retrospectively assess the natural history of ACC lung metastasis and evaluate tumor dynamics using RECIST criteria and tumor volume doubling time (TVDT). (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: L.G. Sousa, E. Andreazza Dal Lago, Z. Yang, C.O. Hoff, F. Bonini, M. Sawyer, K. Wang, W. Lewis, K.A. Wahid, E.Y. Hanna, A.K. El-Naggar, C.D. Fuller, S. Kundu, M. Godoy, R. Ferrarotto Tags: 244 Source Type: research
The KEYNOTE-630 Trial: A Phase 3 Study of Adjuvant Pembrolizumab in High-Risk Locally Advanced (LA) Cutaneous Squamous Cell Carcinoma (cSCC)
In high-risk LA cSCC, approximately 20% of patients (pts) experience local disease recurrence within 5 years after surgical resection and adjuvant radiotherapy (RT). Therefore, improved treatment options are needed. The PD-1 inhibitors pembrolizumab (pembro) and cemiplimab have demonstrated durable antitumor activity in advanced metastatic cSCC. The randomized, double-blind, placebo-controlled, phase 3 KEYNOTE-630 (NCT03833167) trial will evaluate adjuvant pembro in pts with resectable, high-risk, LA cSCC. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: M. Schenker, M. Klochikhin, D. Kirtbaya, L. Mortier, M. Gschnell, C. Robert, N. Meyer, L. Flatz, S. Dalle, M. Beylot-Barry, T. Eigentler, R. Kloss Silverman, B. Gumuscu, J. Yuan, A. Bratland Tags: 245 Source Type: research
Mucoepidermoid Carcinoma in the Oropharynx: A Review of the Literature
There is a lack of evidence-based recommendations for patient work up, counseling, and management of mucoepidermoid carcinoma of the oropharynx (OPMEC). We aim to perform a systematic review and summarize the demographics, clinical presentation, histology, treatment, and oncologic outcomes of OPMEC. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: G.A. Calcano, A.E. Brown, E.J. Moore, D.L. Price, K.K. Tasche, L.X. Yin, K.M. Van Abel Tags: 246 Source Type: research
Prognostic Performance of Sentinel Lymph Node Biopsy for the Clinically Negative Neck in High-Risk Cutaneous Squamous Cell Carcinoma
Even though cutaneous squamous cell carcinoma (cSCC) is one of the most commonly diagnosed malignancies in the United States, there is a lack of prospective data that can inform risk stratification for regional metastasis in the clinically node-negative neck. Regional nodal disease is considered the strongest predictor for recurrence and survival, yet available literature on the rate of occult regional metastases is largely limited to retrospective reviews. Sentinel lymph node biopsy (SLNB) is standard of care and established as a major prognostic marker for melanoma, yet its role in the management of high risk cSCC has no...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J.L. Farlow, A.J. Jones, D.X. Xie, D.W. Chen, D.A. Campbell, M. Sim, A. Mantravadi, M.G. Moore, G. Durm, A.K. Somani, J. Yesensky Tags: 247 Source Type: research
Local Therapy in the Management of Mucosal Melanoma: An NCDB Analysis
This study aims to determine the survival benefit of immunotherapy, surgery and radiation in setting of mucosal melanoma. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: R.A. Ishteiwy, M. Townsend, E. Cash, Z. Liu, M. Kong, D. Crawford, T. Gupta, L. Kahloon, N.E. Dunlap Tags: 248 Source Type: research
Phase II trial of Abemaciclib in Unresectable or Metastatic Anaplastic Thyroid Cancer
We report our clinical trial with abemaciclib, an oral CDK4/6 inhibitor, in patients with incurable ATC after FDA-approved treatment options. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: S. Sheth, R. Lu, H. Zhu, E. Ugwu, F. Qin, H. Morton, M. Steffen, C. Miles, E. Winters, S. Lai, H. Kang, V. Khanna, S. Khan Tags: 249 Source Type: research
Reflectance Confocal Microscopy Mapping of Non-melanoma Skin Cancers to Guide Definitive Radiation Therapy
Basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) are the most prevalent non-melanoma skin cancer types (NMSCs). For patients with lesions in cosmetically challenging areas or for patients with significant comorbidities, non-surgical management with radiation therapy can be an excellent alternative to surgery. As a surrogate for pathological margin assessment of surgical techniques, non-invasive tools to define the at-risk area can be extremely helpful when employing radiation, to preserve normal tissue from radiation side effects and minimizing the risk of local recurrence concurrently. (Source: Internation...
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J. Madsen, N.F. Braghiroli, S. Yarlagadda, M. Rubens, N.S. Kalman Tags: 250 Source Type: research
Hypofractionated Radiotherapy for Merkel Cell Carcinoma
Merkel cell carcinoma (MCC) is a radiosensitive skin cancer. Historically, radiation treatment for MCC has involved standard 1.8-2 Gy fractions treated daily over 4-6 weeks. For other cutaneous malignancies, radiation treatment with daily doses>2 Gy has increased in prevalence in order to reduce treatment time and increase patient convenience. The equivalence of such hypofractionated treatment regimens to standard fractionation regimens for tumor control and skin toxicity has been shown for common cutaneous malignancies such as basal cell and squamous cell carcinomas. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: L. Gonzalez, S. Yarlagadda, M. Rubens, N.S. Kalman Tags: 251 Source Type: research
First-line ADP-A2M4CD8 T-cell Receptor T-cell Therapy plus Pembrolizumab in Head and Neck Cancers: An Additional Cohort of the Phase 1 SURPASS Trial
ADP-A2M4CD8 is an autologous CD4+ and CD8+ T-cell therapy under investigation for treatment of advanced cancers in human leukocyte antigen (HLA)-A*02 –eligible participants. It expresses a genetically modified T-cell receptor (TCR) targeting melanoma-associated antigen A4 (MAGE-A4) and an additional CD8α co-receptor to increase functionality of CD4+ T cells. ADP-A2M4CD8 monotherapy has demonstrated an acceptable benefit-risk profile in the ong oing Phase 1 SURPASS trial (NCT04044859), with clinical responses in multiple tumor types in the late-line setting. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: A. Ho, A. Garcia-Consuegra, J. Saro, A. Sauer, S. Cristiani, F.E. Brophy, S. Streets, E. Norry, M. Gillison, J. Charlson, M. Bover, J. Zugazagoitia, E. Calvo, L. Ugidos, G. Bruixola, V. Moreno Garcia, D.S. Hong, J. Rubio-P érez, D.H. Aggen Tags: 252 Source Type: research
Neoadjuvant Immunotherapy for Regional Metastatic Melanoma: A Systemic Review and Meta-analysis
Neoadjuvant immunotherapy has emerged as a potential solution to improve outcomes for patients with advanced resectable melanoma, particularly in the head and neck region, where the disease is prevalent. Despite advances in adjuvant immunotherapy, locally advanced melanoma continues to pose significant morbidity and mortality challenges. This review aims to evaluate the effectiveness of neoadjuvant immunotherapy for stage III locally metastatic melanoma, considering its impact on pathological response and adverse events. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: A. Belnap, J. Bergeron, M. Dial, E. McCoul, B. Moore Tags: 253 Source Type: research